Drug profile · INN
prabotulinumtoxina-xvfs
JEUVEAU
prabotulinumtoxina-xvfs (JEUVEAU) is a synaptosomal nerve-associated protein 25 (snap-25) proteolytic enzyme. Route of administration: injection. Current US regulatory status: approved.
Drug details — prabotulinumtoxina-xvfs
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
prabotulinumtoxina-xvfs (JEUVEAU) is a synaptosomal nerve-associated protein 25 (snap-25) proteolytic enzyme. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Synaptosomal nerve-associated protein 25 (SNAP-25) proteolytic enzyme
Primary target: Synaptosomal-associated protein 25
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is prabotulinumtoxina-xvfs?
prabotulinumtoxina-xvfs (JEUVEAU) is a synaptosomal nerve-associated protein 25 (snap-25) proteolytic enzyme. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for prabotulinumtoxina-xvfs?
JEUVEAU is a marketed brand name for prabotulinumtoxina-xvfs. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of prabotulinumtoxina-xvfs?
prabotulinumtoxina-xvfs has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.